GD3 is a disialoganglioside that functions as a critical surface antigen expressed at high levels on many malignant melanoma cells, as well as on certain other neuroectodermal tumors and some leukemias. In normal adult tissues, GD3 expression is generally low or restricted, making it a attractive tumor-associated antigen for targeted therapy. Its overexpression on cancer cells is often linked to enhanced malignant properties, including increased proliferation, invasion, and metastasis.